研究室について

これまでの実績

2016年 (total impact fac. 92.375 ave. 8.398)

Kamata, T., Suzuki, A., Mise, N., Ihara, F., Takami, M., Makita, Y., Horinaka, A., Harada, K., Kunii, N., Yoshida, S., Yoshino, I., Nakayama, T., and Motohashi, S.: Blockade of programmed death-1/programmed death ligand pathway enhances the antitumor immunity of human invariant natural killer T cells. Cancer Immunol. Immunother. 65:1477-1489 (2016). (4.846)

Hayashizaki, K.,* Kimura, M. Y.,* Tokoyoda, K.,* Hosokawa, H., Shinoda, K., Hirahara, K., Ichikawa, T., Onodera, A., Hanazawa, A., Iwamura, C., Kakuta, J., Muramoto, K., Motohashi, S., Tumes, D. J., Iinuma, T., Yamamoto, H., Ikehara, Y., Okamoto, Y., and Nakayama, T.: Myosin light chain 9 and 12 are functional ligands for CD69 that regulate airway inflammation. (*these authors contributed equally to this work) Sci. Immunol. 1:pp.eaaf9154 (2016).

Takamura, S., Yagi, H., Hakata, Y., Motozono, C., McMaster, S. R., Masumoto, T., Fujisawa, M., Chikaishi, T., Komeda, J., Itoh, J., Umemura, M., Kyusai, A., Tomura, M., Nakayama, T., Woodland, D. L., Kohlmeler, J. E., and Miyazawa, M.: Specific niches for lung-resident memory CD8+ T cells at the site of tissue regeneration enable CD69-independent maintenance. J. Exp. Med. 213:3057-3073 (2016). (11.240)

Endo, Y., Hirahara, K., Shinoda, K., Iinuma, T., Yamamoto, H., Motohashi, S., Okamoto, Y., and Nakayama, T.: Human and mouse memory-type pathogenic Th2 (Tpath2) cells in airway inflammation. Chronic Inflammation Mechanisms and Regulation 401-415 (2016).

Angela, M.,* Endo, Y.,* Asou, H. K., Yamamoto, T., Tumes, D. J., Tokuyama, H., Yokote, K., and Nakayama, T.: Fatty acid metabolic reprogramming via mTOR-mediated induction of PPARγ directs early activation of T cells. (*these authors contributed equally to this work) Nat. Commun. 7:13683 (2016). (11.329)

Kimura, M. Y., Thomas, J., Tai, X., Guinter, T. I., Shinzawa, M., Etzenperger, R., Li, Z., Love, P., Nakayama, T., and Singer, A.: Timing and duration of MHC I positive selection signals are adjusted in the thymus to prevent lineage errors. Nat. Immunol. 17:1415-1423 (2016). (19.381)

Nakano, M., Kamada, N., Suehiro, K., Oikawa, A., Shibata, C., Nakamura, Y., Matsue, H., Sasahara, Y., Hosokawa, H., Nakayama, T., Nonaka, K., and Ohara, O.: Establishment of a new three-dimensional human epidermal model reconstructed from plucked hair follicle-derived keratinocytes. Exp. Dermatol. 25:903-906 (2016). (2.675)

Kuwahara, M., Ise, W., Ochi, M., Suzuki, J., Kometani, K., Maruyama, S., Izumoto, M., Matsumoto, A., Takemori, N., Takemori, A., Shinoda, K., Nakayama, T., Ohara, O., Yasukawa, M., Sawasaki, T., Kurosaki, T., and Yamashita, M.: Bach2-Batf interactions control Th2-type immune response by regulating the IL-4 amplification loop. Nat. Commun. 7:12596 (2016). (11.329)

Shinoda, K., Hirahara, K., Iinuma, T., Ichikawa, T., Suzuki, A. S., Sugaya, K., Tumes, D. J., Yamamoto, H., Hara, T., Tani-ichi, S., Ikuta, K., Okamoto, Y., and Nakayama, T.: Thy1+IL-7+ lymphatic endthelial cells in iBALT provide a survival niche for memory T-helper cells in allergic airway inflammation. Proc. Natl. Acad. Sci. USA 113:E2842-51 (2016). (9.423)

Hosokawa, H., Tanaka, T., Endo, Y., Kato, M., Shinoda, K., Suzuki, A., Motohashi, S., Matsumoto, M., Nakayama, K. I., and Nakayama, T.: Akt1-mediated Gata3 phosphorylation controls the repression of IFNγ in memory-type Th2 cells. Nat. Commun. 7:11289 (2016). (11.329)

Hirahara, K., and Nakayama, T.: CD4+ T-cell subsets in inflammatory diseases: beyond the Th1/Th2 paradigm. Int. Immunol. 28:163-171 (2016). (3.031)

Mise, N., Takami, M., Suzuki, A., Kamata, T., Harada, K., Hishiki, T., Saito, T., Terui, K., Mitsunaga, T., Nakata, M., Ikeuchi, T., Nakayama, T., Yoshida, H., and Motohashi, S.: Antibody-dependent cellular cytotoxicity toward neuroblastoma enhanced by activated invariant natural killer T cells. Cancer Sci. 107:233-241 (2016). (3.896)

Horinaka, A., Sakurai, D., Ihara, F., Makita, Y., Kunii, N., Motohashi, S., Nakayama, T., and Okamoto, Y.: Invariant NKT cells are resistant to circulating CD15+ myeloid-derived suppressor cells in patients with head and neck cancer. Cancer Sci. 107:207-216 (2016). (3.896)